for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dova Pharmaceuticals Inc

DOVA.OQ

Latest Trade

28.40USD

Change

0.00(0.00%)

Volume

65,139

Today's Range

28.21

 - 

28.46

52 Week Range

5.62

 - 

28.46

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
28.40
Open
28.30
Volume
65,139
3M AVG Volume
11.07
Today's High
28.46
Today's Low
28.21
52 Week High
28.46
52 Week Low
5.62
Shares Out (MIL)
28.80
Market Cap (MIL)
817.97
Forward P/E
-11.57
Dividend (Yield %)
--

Latest Developments

More

Sobi To Acquire Dova Pharmaceuticals

Dova Pharmaceuticals To Be Acquired By Swedish Orphan Biovitrum AB

Dova Pharmaceuticals Reports Second Quarter 2019 Operating And Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dova Pharmaceuticals Inc

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Company’s product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.

Industry

Biotechnology & Drugs

Contact Info

240 Leigh Farm Rd

+1.919.8064487

http://dova.com/

Executive Leadership

Paul B. Manning

Chairman of the Board

David S. Zaccardelli

President, Chief Executive Officer

Mark W. Hahn

Chief Financial Officer

Kevin Laliberte

Senior Vice President - Product Development

Lee F. Allen

Chief Medical Officer

Key Stats

2.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-1.400

2018

-2.600

2019(E)

-2.455
Price To Earnings (TTM)
--
Price To Sales (TTM)
61.56
Price To Book (MRQ)
16.06
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
40.74
LT Debt To Equity (MRQ)
38.43
Return on Investment (TTM)
-71.38
Return on Equity (TTM)
-63.30

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up